• Catalog No.: S2232
• CAS Number: 74050-98-9
• M. F.: C22H22FN3O3
• M. W.: 395.4267832
• Storage: -20°C

SYNONYMS

• IUPAC name: 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
• IUPAC Traditional name: 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1H-quinazoline-2,4-dione
• Synonyms: R 41468; Vulketan Gel

DATABASE IDS

• CAS Number: 74050-98-9

PROPERTIES

• Target: 5-HT
• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area: Cancer
Biological Activity:
Ketanserin (Vulketan Gel) is specific 5-HT2A serotonin receptor antagonist with a Ki of 2.5 nM for rat and human 5-HT2A. Ketanserin (Vulketan Gel) is a drug with affinity for multiple G protein-coupled receptors. Ketanserin ( Vulketan Gel) inhibits rat and human 5-HT2C with Ki of 50 and100 nM, respectively and has higher affinity binding for alpha-1 adrenergic (Ki = ~ 40 nM) and Histamine H1 (Ki = 2 nM). Ketanserin (Vulketan Gel) can also be used to discriminate between 5-HT1D and 5-HT1B receptor subtypes. Ketanserin (Vulketan Gel) has antihypertensive properties. Ketanserin (Vulketan Gel) also reduces platelet aggregation produced by serotonin. Ketanserin also has high affinity for alpha-1 adrenergic receptors, and very high affinity for histamine H1 receptors. Ketanserin (Vulketan Gel) was shown to reduce the severity and frequency of the vasospasm in Raynaud’s phenomenon. [1][2][3]References on Ketanserin (Vulketan Gel)[1] http://en.wikipedia.org/wiki/Ketanserin, , [2] Neurochem Int., 1995 Dec, 27(6):489-96.[3] Eur J Pharmacol., 1991 Jan 25, 206(1):39-45.

REFERENCES

• Rego AC et al. Neurochem Int. 1995 Dec; 27(6):489-96.